Casdin Partners Master Fund, L.P. 4
4 · STANDARD BIOTOOLS INC. · Filed Nov 20, 2025
Insider Transaction Report
Form 4
Casdin Partners Master Fund, L.P.
Director10% Owner
Transactions
- Purchase
Common Stock, $0.001 par value per share
2025-11-20$1.30/sh+450,000$586,260→ 64,050,000 total(indirect: See footnote) - Purchase
Common Stock, $0.001 par value per share
2025-11-19$1.28/sh+350,000$448,910→ 63,600,000 total(indirect: See footnote) - Purchase
Common Stock, $0.001 par value per share
2025-11-18$1.23/sh+275,000$339,405→ 63,250,000 total(indirect: See footnote)
Holdings
- 2,744,219(indirect: See footnote)
Common Stock, $0.001 par value per share
- 2,901,062
Common Stock, $0.001 par value per share
- 13,939,637(indirect: See footnote)
Common Stock, $0.001 par value per share
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2247 to $1.2421. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2758 to $1.2870. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2788 to $1.3500 . The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
- [F4]The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
- [F5]The securities are owned directly by Eli Casdin.
- [F6]The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
- [F7]The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.